Companies › AltruBio
1 active drug program in 2 registered trials: 1 Phase 2, 1 Phase 1; Immunology; next expected readout Mar 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ALTB-268 monoclonal antibody | – | Phase 2 | Ulcerative Colitis; Ulcerative Colitis (UC) | Mar 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07350577 | ALTB-268 | Phase 1 | Ulcerative Colitis (UC) | Immunology | Apr 2026 |
| NCT06109441 | ALTB-268 | Phase 2 | Ulcerative Colitis | Immunology | Mar 2028 |
No annotated target.
–
Aravax VivaTech International Qu Biologics 4Moving Biotech Bluefin Biomedicine
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.